Intelligence Feed event · Policy · 2026-08-27

    FDA Approves Revolution Medicines' RASONQUE for Metastatic Pancreatic Cancer

    Question

    FDA Approves Revolution Medicines' RASONQUE for Metastatic Pancreatic Cancer

    Direct answer

    Revolution Medicines received FDA approval for RASONQUE (daraxonrasib), making it the first broad RAS inhibitor authorized for patients with metastatic pancreatic adenocarcinoma who progressed on systemic therapy. The product launch will be supported by Onco360 as the designated specialty dispensing partner following data from the registration-enabling RASolute 302 Phase 3 clinical study.

    Original publisher
    Market Ontology
    Evidence through
    2026-08-27
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “FDA Approves Revolution Medicines' RASONQUE for Metastatic Pancreatic Cancer”, revision 1, evidence through 2026-08-27. https://marketontology.com/market-events/2026-08-27/fda-approves-revolution-medicines-rasonque-for-metastatic-pancreatic-cancer-3d3b3a

    POLICY
    FDA Approves Revolution Medicines' RASONQUE for Metastatic Pancreatic Cancer
    Revolution Medicines received FDA approval for RASONQUE (daraxonrasib), making it the first broad RAS inhibitor authorized for patients with metastatic pancreatic adenocarcinoma who progressed on systemic therapy. The product launch will be supported by Onco360 as the designated specialty dispensing partner following data from the registration-enabling RASolute 302 Phase 3 clinical study.
    RVMDIMRX
    Impact
    75
    AUG 27
    SIG
    92%
    RVMDIMRX
    FDA Approves Revolution Medicines' RASONQUE for Metastatic Pancreatic Cancer
    Revolution Medicines received FDA approval for RASONQUE (daraxonrasib), making it the first broad RAS inhibitor authorized for patients with metastatic pancreatic adenocarcinoma who progressed on systemic therapy. The product launch will be supported by Onco360 as the designated specialty dispensing partner following data from the registration-enabling RASolute 302 Phase 3 clinical study.
    → Commercial authorization of RASONQUE establishes first-line commercial oncology cash flows for RVMD through specialized specialty pharmacy distribution networks.
    Impact
    Revolution Medicines received FDA approval for RASONQUE (daraxonrasib), making it the first broad RAS inhibitor authorized for patients with metastatic pancreatic adenocarcinoma who progressed on systemic therapy. The product launch will be supported by Onco360 as the designated specialty dispensing partner following data from the registration-enabling RASolute 302 Phase 3 clinical study.
    Affected
    RVMDIMRX
    Transmission
    Commercial authorization of RASONQUE establishes first-line commercial oncology cash flows for RVMD through specialized specialty pharmacy distribution networks.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    RVMDoncology product commercial revenue realizationUp1-3mFDA approved RASONQUE for metastatic pancreatic adenocarcinoma based on Phase 3 trial.
    IMRXcompetitive repositioning to front-line pancreatic regimensMixed1-4wImmuneering reiterated focus on first-line pancreatic cancer following second-line approval of RASONQUE.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month